• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Hartford Hospital/UCONN Cardiovascular Fellowship - PROGRAM ...
 

Hartford Hospital/UCONN Cardiovascular Fellowship - PROGRAM ...

on

  • 926 views

 

Statistics

Views

Total Views
926
Views on SlideShare
924
Embed Views
2

Actions

Likes
0
Downloads
1
Comments
0

1 Embed 2

http://www.health.medicbd.com 2

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Hartford Hospital/UCONN Cardiovascular Fellowship - PROGRAM ... Hartford Hospital/UCONN Cardiovascular Fellowship - PROGRAM ... Document Transcript

    • PROGRAM DESCRIPTION CARDIOVASCULAR FELLOWSHIP HARTFORD HOSPITAL/UNIVERSITY OF CONNECTICUT Program Director: Gary V. Heller, MD, Ph.D. Associate Director: Ravi Yarlagadda, MD 80 Seymour Street, P.O. Box 5037 Hartford, CT 06102-5037 Director, Cardiology: Paul D. Thompson, MD Associate Director, Cardiology: Gary V. Heller, MD, Ph.D. Director, Cardiovascular Research: Paul D. Thompson, MD Full-Time Faculty: Paul D. Thompson, MD Gary V. Heller, MD, Ph.D. Jeffrey Kluger, MD Ravi Yarlagadda, MD Christopher Clyne, MD Justin B. Lundbye, MD Judy Mangion, MD Francis J. Kiernan, MD CLINICAL FACULTY: Interventional Cardiology Francis J. Kiernan, MD, Director Jeffrey Hirst, MD Charles A. Primiano, MD Daniel Fram, MD Raymond G. McKay, MD Joseph Mitchel, DO Echocardiography Judy Mangion, MD, Director Heart Rhythm Management & Interventional Electrophysiology Jeffrey Kluger, MD, Director Christopher Clyne, MD, Director, Interventional Electrophysiology Ravi Yarlagadda, MD Nuclear Cardiology Exercise Laboratory Gary V. Heller, MD, Ph.D., Director Charles A. Primiano, MD, Director Preventive Cardiology Coronary Intensive Care Unit Paul D. Thompson, MD, Director Justin B. Lundbye, MD, Director Ellen Dornelas, Ph.D. Hospitalists Hermal Kadakia, MD Shafeeq Ahmed, MD Aravind Kokkirala, MD Ravi Kalaga, MD Richard Ruffin, MD Cardiology Attendings Peter Barwick, MD Reza Mansoor, MD James Cardon, MD Maha Mikhail, MD David M. Casey, MD Alfredo Nino, MD James Dougherty, MD Dariush Owlia, MD Brett Duncan, MD Lawrence Pareles, MD Melissa Ferraro-Borgida, MD Ronald Pariser, MD Carol Gemayel, MD Asad Rizvi, MD Steve Goldblatt, MD Michael Rossi, MD Steve Horowitz, MD Fred Rubin, MD James Kallal, MD Donald Ruffett, MD Stephen Kastoff, MD Kevin Tally, MD Anthony LaSala, MD Jeffrey Walden, MD
    • 2 General Description The Cardiovascular Disease Program at Hartford Hospital/University of Connecticut is a three- year program specifically designed to prepare cardiovascular fellows for the practice of Cardiology. While in the three-year program, fellows receive training in basic cardiovascular diseases, clinical cardiology, and subspecialty practices. This is accomplished in several ways including clinical rotations which allows exposure to cardiovascular related diseases and problems, didactic sessions covering basic mechanisms of cardiovascular diseases, dedicated research months and subspecialty rotations. During the clinical rotations, the cardiovascular disease fellow interviews, examines and formulates basic evaluations in patients with cardiovascular related illnesses. During subspecialty training, cardiovascular disease fellows are exposed to the practices of cardiac catheterization, preventive cardiology, arrhythmias, nuclear cardiology, echocardiography, cardiovascular surgery, pacemaker techniques and interventional electrophysiology. During the third year, the cardiovascular disease fellow chooses either an invasive or non-invasive track for additional training in one of those areas. At the completion of the cardiovascular disease program, the fellow is qualified to enter the practice of cardiovascular diseases either in the invasive, non-invasive or clinical areas. Although, not specifically part of the cardiovascular disease program, interested fellows may choose a fourth year subspecializing in various aspects of cardiology in hopes of pursuing an academic career. The Interventional Cardiology Program at Hartford Hospital is ACGME approved and is an option for further training. The research experience in the cardiovascular disease program is designed to allow the fellow ample exposure to the process of designing, performing data analysis, and manuscript preparation of a research project. Research is begun in the first year specifically to allow the cardiovascular disease fellow opportunity to gain skill and knowledge in the performance of cardiovascular disease research and to allow time for completion of study. The early exposure to research also allows the fellow the opportunity to evaluate the possibility of entering academic cardiology. Fellows engaged in research are expected to prepare results for abstract and manuscript submission. Local hospital funding is available for support of projects, and several attending physicians have national support for studies. Dr. Paul D. Thompson is supervisor of the research experience for the fellows. Fellowship Length and Rotations
    • 3 The University of Connecticut/Hartford Hospital Cardiovascular Disease Fellowship Program consists of a 3-year blend of Clinical Cardiology, subspecialty training, and research. Hartford Hospital is one of the largest cardiovascular volume hospitals in the New England area and exposes the fellows to a wide range of cases, which will be encountered in future cardiovascular practice. The 1st year is primarily clinical and includes the consultation service, coronary care unit, and subspecialties of arrhythmia, echocardiography, nuclear cardiology, cardiac catheterization, and preventive cardiology. One month is set aside for research. The duties of the fellows are to gain knowledge in the various subspecialties and how they interact with clinical cardiology. Early exposure to subspecialties that separates the cardiology fellow from their internal medicine background is a key component of the program prior to CICU and Consultation rotations. The 2nd year is a similar format to the 1st year rotations with the exception of 2 months of research and elective time. In the 2nd year the fellow has more in depth exposure to clinical cardiovascular medicine as well as each of the subspecialties, and assumes greater responsibilities. The 3rd year fellow can choose two pathways between invasive and non-invasive cardiology. If the fellow chooses the invasive pathway, 9 months are spent in the cardiac catheterization laboratory and 3 months in research. A non-invasive pathway includes rotations in nuclear cardiology, echocardiography, and 3 months of research, which can be tailored to the individual fellow needs. Conference Schedule The fellows attend daily conferences, which include non-invasive cardiology, cardiac catheterization, arrhythmia/ECG, journal club, cardiology grand rounds, lipid management, research combined surgical/cardiac rounds and chief’s rounds. . For each lecture series, presentations include basic descriptions of the subspecialty as well as clinical discussions. Cardiology grand rounds consists of nationally recognized speakers discussing all relevant topics in cardiology. Once a month the fellows have the opportunity to meet with and present cases to an outside expert. In addition, the fellows undergo a 2-month course in cardiovascular diseases in July and August of each year. This course is designed to acquaint the incoming
    • 4 fellows with acute situations they may encounter as well as topics that may not be covered in other venues. EDUCATIONAL PROGRAM Clinical Cardiology Service: The Clinical Cardiology Service consists of both the Coronary Intensive Care Unit (CICU) and the Consultation Service. The concept is to provide a strong basis of clinical training for the fellow. CICU: The cardiology fellow is responsible for training of residents and supervision of all patients in the CICU. Approximately 80% of patients admitted to the Coronary Care Unit are in conjunction with private attendings, another 20% of patients are on the Cardiology Service. The Cardiology Fellow is indirectly responsible for the general well being of all patients but directly responsible for all Cardiology Service patients in conjunction with the Cardiology Service attending. The fellow in conjunction with the CICU attending rounds daily with the house staff providing important educational opportunities. The cardiology fellow is responsible for all cardiac emergencies in the hospital during the rotation. Consultation Service: The Consultation Service at Hartford Hospital is responsible for all requests for cardiology consultations by in-hospital services. These services include internal medicine, surgery, obstetrics/gynecology, neurosurgery, etc. These consultations include such topics as preoperative evaluation, cardiac contusion, management of acute coronary syndromes, and congestive heart failure. The Cardiology Fellow in conjunction with the service attending evaluates all patients, performs physical examinations, and develops a diagnostic and management strategy. The attending physician with the Cardiology Fellow sees and evaluates all patients who undergoes cardiac consultation. In addition, the Cardiology Fellow is responsible the Chief’s Cardiology Service. These are admitted patients who have no assigned physician. Up to 4 patients may be admitted with such diagnoses as acute coronary syndrome, congestive heart failure, bacterial endocarditis, and other cardiovascular related illnesses. An intern from the CICU rotation follows the patient with the Cardiology Fellow. Outpatient Cardiovascular Clinic: An important part of the cardiovascular fellowship is the Outpatient Cardiovascular Clinic. Sessions are held Wednesday morning and Thursday afternoon on a weekly basis. Cardiovascular Fellows are assigned to one of these times and continue that time throughout the year. Unassigned patients who choose to receive services at the Brownstone Clinic are seen by Cardiology Fellows. These include patients with chronic stable angina, multiple valvular disorders, congestive heart failure, and arrhythmias. An attending physician is assigned to the clinic. The attending physician examines, and develops
    • 5 management strategies with the Cardiovascular Fellow. In addition to the unassigned patient, any recently hospitalized patient is followed in the Cardiovascular Clinic. Patients are also referred from the Internal Medicine Clinics seen in the same building. After an initial evaluation, the patients seen by the Cardiology Fellow may be followed for the duration of the Cardiovascular Fellow’s tenure. It is expected that the Cardiology Fellow will follow any patients from the Cardiovascular Clinic who are hospitalized. The fellow in conjunction with the Consultation/CICU fellow will assist in diagnostic and management decisions. The Outpatient Cardiovascular Clinic is a rich and rewarding part of the Cardiovascular Fellowship. This experience gives the Fellows long-term longitudinal exposure to further refine management strategies over time. Hartford Hospital is a primary and tertiary care center with referrals from the northern Connecticut area. Heart Rhythm Management/Interventional Electrophysiology Service: Heart Rhythm Management Services at Hartford Hospital consist of a diagnostic and interventional electrophysiology laboratories, Syncope Center, one of the largest device clinics in the region (8,000 encounters/year) and a busy consultation service. During the first year the fellow performs consultations in conjunction with the attending physician and assists in various studies such as electrophysiologic testing, tilt-table testing, holter monitoring and arrhythmia recognition. Fellows attend pacemaker and ICD clinics and learn device interrogation and programming. The heart rhythm management service is a busy one with over 1,000 consultations annually. EP studies and tilt-table tests are performed on a daily basis. Catheter ablation and biventricular pacing procedures are on the cutting edge of interventional electrophysiology. The goals of the first year are to become skilled at identification and treatment of arrhythmias, understand the role of electrophysiology and tilt studies and to perform device interrogation. The 2nd year fellow performs at least one month and possibly two months of advanced training and is expected to be more skilled in the evaluation of patients with arrhythmias as well as the performance of related procedures such as tilt-table testing, EPS, and assisting in catheter ablations. Cardiac Catheterization: Hartford Hospital has an active catheterization program. The facility consists of four adult cardiac catheterization suites equipped with digital x-ray systems. On an
    • 6 annual basis approximately 3700 procedures are performed including 1200 coronary interventional procedures. The patients who are referred to the laboratory represent a broad spectrum of cardiac pathology. The procedures offered include diagnostic cardiac catheterization, balloon angioplasty, coronary stent placement and the use of new and investigational devices. The vast majority of patients who present to Hartford Hospital with acute myocardial infarction are referred to the laboratory for primary intervention. The teaching faculty consists of seven cardiologists who are geographically based in the laboratory. Fellows in the first and second year of training are exposed to diagnostic right and left heart catheterization including coronary angiography. They participate in the pre-procedure evaluation of the patient and participate with the attending in the performance of the procedure and interpretation of results. The major emphasis in the first two years is acquiring knowledge of basic coronary anatomy and hemodynamics. Fellows in their third year can elect to spend nine months in the laboratory in order to obtain in-depth training in cardiac catheterization. Hartford Hospital also offers a dedicated fourth year of training in interventional cardiology, an ACGME approved program. In addition to clinical activities and teaching, the fellows have an opportunity to participate in the research activities of the laboratory. There is an active patient database that can be used for clinical research. The laboratory is involved with testing of new devices as part of clinical trials. There is also an animal facility for basic research. These activities have resulted in a number of presentations and publications by cardiology fellows. Echocardiography Laboratory: The Echocardiography Laboratory performs over 7,000 studies annually. Equipment includes state of the art Siemens and Phillips systems with emergency imaging performed 24 hours a day. The Echocardiography section provides comprehensive didactic and clinical training in the performance and interpretation of Echocardiograms. Training includes hands-on acquisition of transthoracic images with digital and tape storage and retrieval technology. The basics of ultrasound and Doppler physics are taught at length in didactic sessions. The fellow will become adept at performance and interpretation of complete transthoracic echocardiograms. Tools such as M-mode, second harmonic imaging, contrast echocardiography and power Doppler will be used on routine clinical examinations to enhance the diagnostic information obtained from the test. The first year fellow will spend 2 months in Echocardiography and will be expected to perform transthoracic echocardiograms on call with the assistance and backup of a Cardiac Sonographer and Attending. Research participation is encouraged. The objective of the first year in
    • 7 Echocardiography is to become adept at the utilization of echocardiography in clinical practice as a diagnostic tool. The second year fellow will continue with regularly scheduled didactic sessions reviewing the basic principles of Echocardiography. The fellow will continue to advance manual skills in the independent performance of transthoracic echocardiograms. The fellow will also be asked to regularly interpret complete transthoracic echocardiograms with a focus on providing a clinical diagnosis and a thorough interrogation of associated cardiac abnormalities. The objective of the second year in Echocardiography is to become adept at the independent performance and interpretation of complete transthoracic echocardiographic studies. The objective of the third year noninvasive Echocardiography program is to add procedural skills. The fellow will be trained in the performance of transesophageal and stress echocardiography (exercise treadmill and dobutamine stress). The fellow will continue active involvement in the didactic sessions and clinical performance and interpretation of transthoracic echocardiograms. The fellow who chooses the noninvasive path will spend 3-6 months in Echocardiography. A supplemental program is available for those who wish to sit for the ASE examination in Echocardiography. Nuclear Cardiology: The Nuclear Cardiology Laboratory is an integral part of the Cardiology Division and performs over 3,500 nuclear cardiology procedures annually. Equipment includes 3 dual head cameras on site and 3 satellite office locations as well as stress testing with oxygen consumption equipment. The Nuclear Cardiology Laboratory is part of the Cardiology Division and directed by a board certified nuclear cardiologist. Procedures include a myocardial perfusion imaging associated with gated-SPECT imaging, radionuclide ventriculography, shunt studies, myocardial infarct avid imaging as well as several experimental procedures with new radiopharmaceuticals in the development stages. The pharmacologic stress testing includes vasodilator stress with both dipyridamole and adenosine as well as inotropic stress with dobutamine. Cardiology fellows in the first and second year of training are exposed to four months of dedicated nuclear cardiology which afford them ample opportunity to perform exercise and pharmacology stress testing, and interpret nuclear cardiology procedures with an attending physician. The indications for the procedure as well as clinical implications of findings are discussed. A Non-Invasive conference shared by Echocardiography is held weekly. During the second year the fellow is expected to spend time with technologists to gain an understanding of image acquisition processing and quality control. Time is spent learning technical problems that
    • 8 can occur during the acquisition and processing of nuclear procedures. Fellows in the third year who opt to seek certification in nuclear cardiology may enroll in the University of Connecticut Nuclear Medicine Division Radiation Physics Course to gain certification of the 200 didactic hours required by the Nuclear Regulatory Commission. The third year fellow may gain enough participation for either Level 2 or Level 3 by ACC guidelines. The Level 3 accreditation requires one full year of participation in nuclear cardiology and allows the fellow to fully operate a nuclear cardiology laboratory. An optional fourth year of dedicated research is also possible. Preventive Cardiology: The Preventive Cardiology experience is integrated into the fellowship program with the concept that all well-trained cardiologists should know the principles of primary and secondary heart disease prevention. Preventive Cardiology includes the Cholesterol Management Center, the Nicotine Treatment Center, the Cardiac Rehabilitation Program, and the Exercise Research Program. First year fellows spend a one-month rotation in Preventive Cardiology. The fellow spends time in the Cholesterol Management Center addressing difficult lipid cases, attends smoking cessation clinic, and assists with Cardiac Rehabilitation. There are also didactic sessions provided to all fellows monthly to discuss preventive strategies. By the completion of the fellowship program, the fellow will know advanced lipid physiology, how the lipid lowering agents work, how to counsel patients in smoking cessation, the principles of exercise physiology and how they apply to active patients, and basic hypertension management. Research: The ACGME requires a minimum of 6 months research during the cardiovascular fellowship program. Each fellow is therefore expected to participate in active research projects during his/her fellowship period. Ample opportunity is provided for such experience beginning in the first year. Each year the fellow is expected to become more independent in his/her research but always with the guidance of a mentor. The research fellow is at liberty to choose any attending physician they wish for such guidance. The research environment at Hartford Hospital is extremely strong with participation in both independent and multi-center research projects. The fellows are encouraged to participate in independent research during the fellowship years. Funding is available if necessary through the Research Administration at Hartford Hospital. During the second and third years, if research has progressed, the fellow is encouraged to submit abstracts for the American Heart Association and American College of Cardiology meetings in addition subspecialty meeting applications are also possible. If accepted the fellow is expected to prepare the abstracts for presentation and move towards manuscript preparation. Recent publications by the Division of Cardiology are provided to demonstrate the productivity of the Division.
    • 9 The fellows’ progress is reviewed by a Residency Committee, which meets twice a year. In addition, the Program Director meets every 3 months with the fellow to discuss their evaluations by the attendings. The fellows’ research progress is also discussed during this time. The Program Director meets monthly with all fellows to discuss new information, problems and successes of the cardiovascular disease program.
    • 10 R e c e n t P u b l i c a t i o n s b y t h e C a r d i o l o g y D i v i s i o n Gillespie EL, Gryskiewicz A, White CM, Kluger J, Humphrey C, Horowitz S, Coleman CI. Effect of aprotinin on the frequency of postoperative atrial fibrillation or flutter. Am J Health-Syst Pharm 2005;62:1370-74. Giedrimas A, Guertin D, Clyne CA, Giedrimiene D, Kluger J. Outcomes of ICD therapy for primary and secondary prevention indications. Materials of 26th Annual Scientific Sessions of Heart Rhythm Society. Heart Rhythm J, v. 2, 2005, S168. Giedrimiene D, Guertin D, Clyne CA, Kluger J. Clinical predictors of mortality in patients with syncope and ICD therapy. Materials of 26th Annual Scientific Sessions of Heart Rhythm Society. Heart Rhythm J, v. 2, 2005, S324. Min B, McBride BF, Kardas MJ, Ismali A. Sinha V, Kluger J, White, CM. Electrocardiographic effects of an Ephedra free multicomponent weight loss supplement in healthy volunteers. Pharmacotherapy 2005;25:654-9. Gillespie EL, Perkerson KA, White CM, Kluger J, Coleman CI. Effect of Aprotinin on the incidence of postoperative atrial fibrillation after cardiothoracic surgery. American Journal of Health- System Pharmacy 2005;62:1370-4. Min B, McBride BF, Ismali, Kardas MJ, Sinha V, Kluger J, White CM. The hemodynamic effects of an Ephedra free multicomponent weight loss supplement in healthy volunteers. American Journal of Health-System Pharmacy 2005;62:1582-5. Henyan NH, Gillespie EL, White CM, Kluger J, Coleman CI. The impact of intravenous Magnesium on post-cardiothoracic surgery atrial fibrillation and length of hospital stay: A Meta- Analysis. Annals of Thoracic Surgery 2005;80:2402-2406. Kalus JS, White CM, Caron MF, Guertin D, McBride BF, Kluger J. The impact of elevations in catecholamine concentrations on defibrillation threshold in patients with implanted cardioverter defibrillators. The Defibrillation Threshold Effects of Catecholamines Trial (DTECT). PACE 2005;28:1147-56. McBride BF, Min B, Guertin D, Kluger J, Henyan N, Coleman CI, Silver B, White CM. An evaluation of the impact of oral Magnesium Lactate on the corrected QT interval of patients receiving Sotalol or Dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. Annals Noninvasive Electrocardiology. 2006;11:163-9. Min B, Cios D, Kluger J, White CM. The hemodynamic and electrocardiographic effect of bitter orange extract in healthy volunteers. Pharmacotherapy. 2005;25:1719-24 Kapetanopoulous A, Peckham G, Kiernan F, Clyne C, Kluger, J, Migeed MA. Implantation of a biventricular pacing and defibrillator device via a persistent left superior vena cava. J Cardiovasc Med 2006 7;430-433
    • 11 Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E; JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.Circulation. 2005;111(25):3366-73 Elkoustaf RA, Mamkin I, Mather JF, Murphy D. Hirst JA, Kiernan FJ, McKay RG. Comparison of results of percutaneous coronary intervention for non-ST-elevation acute myocardial infarction or unstable angina in men versus women. Am J Cardiol 2006;98:182-6 Coleman CI, McKay RG, Boden WE, Mather JF, White CM. Effectiveness and cost-effectiveness of facilitated percutaneous coronary intervention compared with primary coronary intervention in patients with ST-segment elevation myocardial infarction transferred from community hospitals. Clinical Therapeutics 2006;28(7):1054-1062. Seip RL, Otvos J, Bilbie C, Tsongalis GJ, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos TJ, Pescatello L, Moyna N, Thompson PD. The effect of apolipoprotein E genotype on serum lipoprotein particle response to exercise. Atherosclerosis. 2006 Sep;188(1):126-33. Guidry MA, Blanchard BE, Thompson PD, Maresh CM, Seip RL, Taylor AL, Pescatello LS.The influence of short and long duration on the blood pressure response to an acute bout of dynamic exercise. Am Heart J. 2006 Jun;151(6):1322.e5-12. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller RF, Devaney JM, Hoffman EP. ACE ID genotype and the muscle strength and size response to unilateral resistance training. Med Sci Sports Exerc. 2006 Jun;38(6):1074-81. Urso ML, Scrimgeour AG, Chen YW, Thompson PD, Clarkson PM. Analysis of Human Skeletal Muscle after 48h Immobilization Reveals Alterations in mRNA and Protein for Extracellular Matrix Components. J Appl Physiol. 2006 Jun 8 Baghdasarian SB, Thompson PD. How safe are very low LDL cholesterol levels? Nat Clin Pract Cardiovasc Med. 2006 Jun;3(6):306-7. Clarkson PM, Kearns AK, Rouzier P, Rubin R, Thompson PD. Serum creatine kinase levels and renal function measures in exertional muscle damage. Med Sci Sports Exerc. 2006 pr;38(4):623- 7. Kapetanopoulos A, Kluger J, Maron BJ, Thompson PD. The congenital long QT syndrome and implications for young athletes. Med Sci Sports Exerc. 2006 May;38(5):816-25. Pelliccia A, Thompson PD. The genetics of left ventricular remodeling in competitive athletes. J Cardiovasc Med (Hagerstown). 2006 Apr;7(4):267-70. Review. Roberts BH, Thompson PD. Is there evidence for the evidence-based guidelines for cardiovascular disease prevention in women? Gend Med. 2006 Mar;3(1):5-12. No abstract available. Thompson PD, Clarkson PM, Rosenson RS; The National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol. 2006 Apr 17;97(8A):69C-76C.
    • 12 Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis. 2006 Mar 16; Blanchard BE, Tsongalis GJ, Guidry MA, LaBelle LA, Poulin M, Taylor AL, Maresh CM, Devaney J, Thompson PD, Pescatello LS. RAAS polymorphisms alter the acute blood pressure response to aerobic exercise among men with hypertension. Eur J Appl Physiol. 2006 May;97(1):26-33. Ouyang P, Tardif JC, Herrington DM, Stewart KJ, Thompson PD, Walsh MN, Bennett SK, Heldman AW, Tayback MA, Wang NY; for the Estrogen And Graft Atherosclerosis Research (EAGAR) investigators. Randomized trial of hormone therapy in women after coronary bypass surgery Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis. 2006 Jan 23; Thompson PD, Tsongalis GJ, Ordovas JM, Seip RL, Bilbie C, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos TJ, Pescatello L, Moyna N. Angiotensin-converting enzyme genotype and adherence to aerobic exercise training. Prev Cardiol. 2006 Winter;9(1):21-4. Patel MD, Thompson PD. Phytosterols and vascular disease. Atherosclerosis. 2006 May;186(1):12-9. Ruano G, Thompson PD, Windemuth A, Smith A, Kocherla M, Holford TR, Seip R, Wu AH. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics. 2005 Dec;6(8):865-72. Juszczyk MA, Seip RL, Thompson PD. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol. 2005 Fall;8(4):197-9. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2560-6. McKenney JM, Davidson MH, Saponaro J, Thompson PD, Bays HE. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol. 2005 Nov;46(5):594- 9. Thompson, PD. Exercise prescription and proscription for patients with coronary artery disease. Circulation. 2005 Oct 11;112(15):2354-63. Review. Thompson PD, Kiernan F. Prevention of heart disease in female athletes. Med Sci Sports Exerc. 2005 Aug;37(8):1440-3. Levine BD, Pelliccia A, Thompson PD, Douglas PS, Fu Q, Di Paolo F, Kiernan F, Zasadil M. The cardiovascular evaluation of women athletes. Med Sci Sports Exerc. 2005 Aug;37(8):1431-2. Ruano G, Seip RL, Windemuth A, Zollner S, Tsongalis GJ, Ordovas J, Otvos J, Bilbie C, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos TJ, Pescatello L, Moyna N, Thompson PD. Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training. Atherosclerosis. 2006 Mar;185(1):65-9. Hubal MJ, Gordish-Dressman H, Thompson PD, Price TB, Hoffman EP, Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Seip RL, Clarkson PM. Variability in muscle size and strength gain after unilateral resistance training. Med Sci Sports Exerc. 2005 Jun;37(6):964-72.
    • 13 Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005 May 17;45(10):1563-9. Thompson PD, Balady GJ, Chaitman BR, Clark LT, Levine BD, Myerburg RJ. Task Force 6: coronary artery disease. J Am Coll Cardiol. 2005 Apr 19;45(8):1348-53. Maron BJ, Douglas PS, Graham TP, Nishimura RA, Thompson PD. Task Force 1: preparticipation screening and diagnosis of cardiovascular disease in athletes. J Am Coll Cardiol. 2005 Apr 19;45(8):1322-6. Review. Levine BD, Thompson PD. Marathon maladies. N Engl J Med. 2005 Apr 14;352(15):1516-8. Jurado J, Thompson PD. Prevention of coronary artery disease in cancer patients. Pediatr Blood Cancer. 2005 Jun 15;44(7):620-4. Review. Clarkson PM, Devaney JM, Gordish-Dressman H, Thompson PD, Hubal MJ, Urso M, Price TB, Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Seip RL, Hoffman EP. ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. J Appl Physiol. 2005 Jul;99(1):154-63. Lundbye JB, Thompson PD. Statin use in the metabolic syndrome. Curr Atheroscler Rep. 2005 Feb;7(1):17-21. Review. Leon AS, Franklin BA, Costa F, Balady GJ, Berra KA, Stewart KJ, Thompson PD, Williams MA, Lauer MS; American Heart Association; Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention); Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity); American association of Cardiovascular and Pulmonary Rehabilitation. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2005 Jan 25;111(3):369-76. Erratum in: Circulation. 2005 Apr 5;111(13):1717. Heller GV. Evaluation of the patient with diabetes mellitus and suspected coronary artery disease. Am J Med 2005;118:9S-14S. Thompson RC, Heller GV, Johnson LL, Case JA, Cullom SJ, Garcia EV, Jones PG, Moutray KL, Bateman TM. Value of attenuation correction on ECG-gated SPECT myocardial perfusion imaging related to body mass index. J Nucl Cardiol 2005;12:195- 202. Sachin M. Navare, M.D., Deborah Katten, R.N., M.P.H., Lynne L. Johnson, M.D., Jeffery F.Mather, M.S., Michael S. Fowler, M.D., Alan W Ahlberg, M.A., Nicholas Miele, B.S., Gary V. Heller, M.D., Ph.D.Risk Stratification with ECG-gated Dobutamine Stress Technetium-99mSestamibi Single Photon Emission Tomographic Imaging: Value of heart rate response and assessment of LV function. JACC 2006;47:781-8.
    • 14 Noble G, Navare S, Katten D, Ahlberg A, O’Sullivan D, Kasapis C, Platt M, Calvert J, Heller GV. Coronary Artery Disease Progression Identified with Repeat Myocardial Perfusion Imaging: An Explanation for Higher Cardiac Event Rates in Diabetic Patients After Normal Stress MPI? 2006 Submitted to Circulation Kapetanopoulos A, Ahlberg AW, Taub CC, O’Sullivan DM, Katten DM, Heller GV. Post- stress Wall Motion Abnormalities from Electrocardiographic-Gated Tc-99m Sestamibi SPECT Predict Cardiac Events. 2006 Submitted to JACC Bateman T, Heller GV, McGhie I, Friedman J, Case J, Bryngelson J, Hertenstein G, Moutray K, Reid K, Cullom SJ. Diagnostic Accuracy of Rest/Stress ECG-gated Rubidium- 82 Myocardial Perfusion PET: Comparison with ECG-gated Tc-99m-Sestamibi SPECT. J Nucl Cardiol 2006;12:24-33. Papaioannou GI, Kasapis, C, Seip RL, Grey NJ, Katten D, Wackers FJ, Inzucchi SE, Engel S, Taylor A, Young LH, Chyun DA, Davey JA, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Heller GV. Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging. J Nucl Cardiol 2006;13:362-8. Chyun DA, Melkus GD, Katten DM, Price WJ, Davey JA, Grey N, Heller GV, Wackers FJTh. The Association of Psychological Factors, Physical Activity, Neuropathy, and Quality of Life in Type 2 Diabetes. Biological Research for Nursing 2006, 7 (4):279-288. Makaryus AN, Gillam LD, Michelakis N, Phillips L, Friedman D, Sison C, Kort S, Rosman D, and *Mangion JR. Contrast echocardiography improves the diagnostic yield of transthoracic studies performed in the intensive care setting by novice sonographers. J Am Soc Echocardiogr. 2005 May;18(5)475-80. Mangion JR and Zubrow ME. New Technologies in Echocardiography: Strain and Strain Rate Imaging. American College of Cardiology, Echo SAP 5. Released, March 2006. Zubrow ME, Siraj Y, Kiernan F, McKay R, Silverman IE, Horowitz S, Gillam LD, and Mangion JR. Atrial septal aneurysm in association with patent foramen ovale predicts persistent residual shunt in CVA patients receiving Cardioseal/Starflex Occluder Device. Poster presented at Annual Scientific Sessions, American College of Cardiology, March 2006. JACC 2006;47(4)152-153A. Zubrow ME, Makaryus AM, Marshall JD, Horowitz S, Gillam LD, and Mangion JR. Echocardiographic features of the cardiomyopathy associated with Alstrom Syndrome: A Retrospective Review. Poster presented at Annual Scientific Sessions, American Society of Echocardiography, June 2006. J Am Soc Echocardiogr. 2006 May:19(5). Gillam LD and Mangion JR. The Beginners’ Guide to Echocardiography: Scanning and Interpretation. Cambridge University Press. Anticipated publication date: December 2006. Prgmde-2.doc